Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study.

PURPOSE To investigate if the extraction flow product (EFP), as determined on dynamic contrast material-enhanced magnetic resonance (MR) images, could be a potential marker of tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. MATERIALS AND METHODS Fourteen women with proven breast cancer underwent MR imaging prior to and following neoadjuvant chemotherapy. Dynamic gradient-echo and echo-planar MR images were acquired before and after injection of gadopentetate dimeglumine. Precontrast T1s were measured before EFP maps were calculated by using a multicompartmental model. Mean EFP (EFPmean) and distribution analysis of EFP (EFPcount) were measured in tumors before and after neoadjuvant chemotherapy and were compared with tumor response at MR imaging. The significance of the difference in EFP values between the responders and nonresponders was calculated with a two-tailed Student t test. RESULTS EFPmean after neoadjuvant chemotherapy in partial responders and nonresponders was 33 mL x 100 g-1 x min-1 +/- 9.8 and 54.2 mL x 100 g-1 x min-1 +/- 10.3, respectively (P <.005). EFPmean decreased after neoadjuvant chemotherapy in the responders and nonresponders by 37% +/- 30 and -5% +/- 35, respectively (P >.05). An increase in EFPmean values was observed only in nonresponders who received taxanes. For regimens without taxanes, EFPmean decreased regardless of the morphologic response. EFPcount decreased for all the responders by 77% +/- 33 and increased for all the nonresponders by 45% +/- 68 (P <.02). CONCLUSION EFPcount appears to provide functional information regarding changes in tumor angiogenesis due to neoadjuvant chemotherapy. Functional MR imaging of the breast may be useful in monitoring tumor response to neoadjuvant chemotherapy.

[1]  A. Leitch,et al.  Multimodality treatment of locally advanced breast carcinoma. , 1988, Archives of surgery.

[2]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[3]  G. Hortobagyi,et al.  Comprehensive management of locally advanced breast cancer , 1990, Cancer.

[4]  G. Hortobagyi,et al.  Feasibility of breast‐conservation surgery after induction chemotherapy for locally advanced breast carcinoma , 1992, Cancer.

[5]  S E Harms,et al.  Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging , 1996, Cancer.

[6]  G. Hortobagyi,et al.  Multimodal treatment of locoregionally advanced breast cancer , 1983, Cancer.

[7]  G. Schwartz,et al.  Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast. , 1987, Archives of surgery.

[8]  Oliver.  Regarding: Valero V, Buzdar AU, Hortobagyi GN. "Locally Advanced Breast Cancer," The Oncologist 1996;1:8-17. , 1996, The oncologist.

[9]  G. Calais,et al.  Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm , 1994, Cancer.

[10]  G. Hortobagyi,et al.  Treatment of breast cancer. , 1998, The New England journal of medicine.

[11]  G. Hortobagyi,et al.  Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. , 1988, Radiology.

[12]  G. Hortobagyi,et al.  Pathological assessment of response to induction chemotherapy in breast cancer. , 1986, Cancer research.

[13]  G. Cocconi,et al.  Problems in evaluating response of primary breast cancer to systemic therapy , 2005, Breast Cancer Research and Treatment.

[14]  T. Powles,et al.  Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma , 1999, Cancer.

[15]  H. Degani,et al.  Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  O Henriksen,et al.  Quantitation of blood‐brain barrier defect by magnetic resonance imaging and gadolinium‐DTPA in patients with multiple sclerosis and brain tumors , 1990, Magnetic resonance in medicine.

[17]  Z. Baloch,et al.  Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.

[18]  J L Evelhoch,et al.  Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.

[19]  W E Reddick,et al.  MR imaging of tumor microcirculation: Promise for the new millenium , 1999, Journal of magnetic resonance imaging : JMRI.

[20]  W. Kraybill,et al.  Multimodal therapy in locally advanced breast carcinoma. , 1990, American journal of surgery.

[21]  G. Calais,et al.  Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers. , 1993, International journal of radiation oncology, biology, physics.

[22]  O Nalcioglu,et al.  Measurement of vascular volume fraction and blood‐tissue permeability constants with a pharmacokinetic model: Studies in rat muscle tumors with dynamic Gd‐DTPA enhanced MRI , 1994, Magnetic resonance in medicine.

[23]  D B Kopans,et al.  Benign and malignant breast lesions: differentiation with echo-planar MR imaging. , 1995, Radiology.

[24]  J. Aisner,et al.  Mastectomy as an adjuvant to chemotherapy for locally advanced or metastatic breast cancer. , 1982, Archives of surgery.

[25]  S. Aamdal,et al.  Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Jaeck,et al.  Results of initial doxorubicin, 5‐fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast , 1990, Cancer.

[27]  H. Degani,et al.  Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. , 1994, Cancer research.

[28]  L. Turnbull,et al.  Dynamic contrast‐enhanced MRI in the differentiation of breast tumors: User‐defined versus semi‐automated region‐of‐interest analysis , 1999, Journal of magnetic resonance imaging : JMRI.

[29]  R. Gilles,et al.  Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. , 1994, Radiology.

[30]  A. Luini,et al.  Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. , 1990, Journal of the National Cancer Institute.

[31]  G. Schwartz,et al.  Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast , 1994, Cancer.

[32]  D B Kopans,et al.  Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. , 1997, Radiology.

[33]  G. Hortobagyi,et al.  Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy , 1988, Cancer.

[34]  G. Hortobagyi,et al.  Treatment of locally advanced breast cancer. , 1992, Seminars in oncology.

[35]  S. Steinberg,et al.  Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. , 1987, Cancer research.

[36]  R K Jain,et al.  Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. , 1999, Cancer research.

[37]  B A Miller,et al.  Recent incidence trends for breast cancer in women and the relevanceof early detection: An update , 1993, CA: a cancer journal for clinicians.